NCT02313376View on ClinicalTrials.gov

Safety, Attenuation and Immunogenicity of GAP3KO Administered Via A Stephensi Mosquitoes

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

August 31, 2015

Conditions
Malaria
Interventions
BIOLOGICAL

GAP3KO

GAP3KO administered via the bite of 150-200 GAP3KO-infected A. stephensi mosquitoes under controlled conditions.

Trial Locations (1)

98109

Seattle Biomedical Research Institute Malaria Clinical Trial Center, Seattle

All Listed Sponsors
lead

Seattle Children's Hospital

OTHER

NCT02313376 - Safety, Attenuation and Immunogenicity of GAP3KO Administered Via A Stephensi Mosquitoes | Biotech Hunter | Biotech Hunter